Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Current Leases (2019 - 2026)

Oramed Pharmaceuticals filings provide 7 years of Current Leases readings, the most recent being $285000.0 for Q4 2025.

  • Quarterly Current Leases rose 31.94% to $285000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $285000.0 through Dec 2025, up 31.94% year-over-year, with the annual reading at $285000.0 for FY2025, 31.94% up from the prior year.
  • Current Leases hit $285000.0 in Q4 2025 for Oramed Pharmaceuticals, up from $271000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $285000.0 in Q4 2025 and bottomed at $129000.0 in Q2 2021.
  • Average Current Leases over 5 years is $221650.0, with a median of $239500.0 recorded in 2022.
  • The largest annual shift saw Current Leases surged 334.38% in 2021 before it dropped 28.74% in 2025.
  • Oramed Pharmaceuticals' Current Leases stood at $130000.0 in 2021, then surged by 90.0% to $247000.0 in 2022, then increased by 8.1% to $267000.0 in 2023, then dropped by 19.1% to $216000.0 in 2024, then soared by 31.94% to $285000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Current Leases are $285000.0 (Q4 2025), $271000.0 (Q3 2025), and $264000.0 (Q2 2025).